- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Everolimus, Exemestane
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 25
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Los Angeles, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 7,250
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Non-clear Cell Renal Cell Carcinoma
- Interventions
- Everolimus, Sunitinib
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Detroit, Michigan + 5 more
- Conditions
- Pain, Pancreatic Cancer
- Interventions
- Cryoablation
- Procedure
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Stony Brook, New York • Cleveland, Ohio
- Conditions
- Down Syndrome, Trisomy 21
- Interventions
- Not listed
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4,664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 8 more
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 33
- States / cities
- Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 16
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 12 more
- Conditions
- Total Atherosclerotic Occlusion of Femoral Artery
- Interventions
- CTO crossing in femoropopliteal arteries CONNECT II
- Device
- Lead sponsor
- Avinger, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Sacramento, California • Elk Grove Village, Illinois + 10 more
- Conditions
- Chronic Myelogenous Leukemia in Chronic Phase
- Interventions
- Nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 32
- States / cities
- Anaheim, California • Burbank, California • Concord, California + 27 more
- Conditions
- HIV Infections, Tuberculosis
- Interventions
- Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1997
- U.S. locations
- 25
- States / cities
- San Francisco, California • Denver, Colorado • New Haven, Connecticut + 15 more
- Conditions
- Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
- Interventions
- AZD 1775
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 13
- States / cities
- Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more
- Conditions
- Excessive Alcohol Consumption
- Interventions
- BASICS motivational interview, BASICS plus normative enhancement motivational interview, Self-directed: Information only
- Behavioral
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 23 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Hematological Malignancy
- Interventions
- Bortezomib
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Hepatitis C
- Interventions
- Sofosbuvir, PEG, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Bakersfield, California + 55 more
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Capivasertib, Paclitaxel, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 923 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- Whittier, California • Fort Myers, Florida • Miami, Florida + 18 more
- Conditions
- Prostate Cancer
- Interventions
- Androgen Deprivation Therapy, bicalutamide, bevacizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 8
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 4 more
- Conditions
- Growth Hormone Deficiency
- Interventions
- TV-1106, dGH
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 32
- States / cities
- Artesia, California • Fountain Valley, California • Lakewood, California + 22 more
- Conditions
- Graft Versus Host Disease
- Interventions
- Prochymal®, Placebo, Standard of Care for GVHD
- Biological · Drug
- Lead sponsor
- Mesoblast, Inc.
- Industry
- Eligibility
- 6 Months to 70 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more
- Conditions
- Neoplasms
- Interventions
- GSK2636771, Enzalutamide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 7
- States / cities
- Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 81
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
- Conditions
- Heart Failure
- Interventions
- GUIDED-HF, Standard of Care
- Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 15
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 11 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- ABT-199, Rituximab, Bendamustine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Atlanta, Georgia + 5 more
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
- Interventions
- belapectin, Placebo
- Drug
- Lead sponsor
- Galectin Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 69 more
- Conditions
- Stem Cell Transplant Complications
- Interventions
- intestinal microbiota
- Diagnostic Test
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan